

α -blockade, apoptosis, and prostate shrinkage: how are they related?

Piotr Chłosta¹, Tomasz Drewa², Steven Kaplan³

¹Department of Urology, Collegium Medicum Jagiellonian University, Kraków, Poland

²Department of Tissue Engineering, N. Copernicus University, Bydgoszcz, Poland; N. Copernicus Hospital, Toruń, Poland

³Weill Cornell Medical College, Cornell University, New York, USA

Article history

Submitted: Jan. 25, 2013

Accepted: Feb. 18, 2013

Correspondence

Tomasz Drewa
Department of Tissue
Engineering
Nicolaus Copernicus
University
24, Karłowicza Street
85-090 Bydgoszcz, Poland
phone: +48 52 58 53 736
tomaszdrewa@wp.

Purpose. The α_1 -adrenoreceptor antagonists, such as terazosin and doxazosin, induce prostate programmed cell death (apoptosis) within prostate epithelial and stromal cells in vitro. This treatment should cause prostate volume decrease. However, this has never been observed in clinical conditions. The aim of this paper is to review the disconnect between these two processes.

Methods. PubMed and DOAJ were searched for papers related to prostate, apoptosis, and stem cell death. The following key words were used: prostate, benign prostate hyperplasia, programmed cell death, apoptosis, cell death, α_1 -adrenoreceptor antagonist, α -blockade, prostate epithelium, prostate stroma, stem cells, progenitors, and in vitro models.

Results. We have shown how discoveries related to stem cells can influence our understanding of α -blockade treatment for BPH patients. Prostate epithelial and mesenchymal compartments have stem (progenitors) and differentiating cells. These compartments are described in relation to experimental in vitro and in vivo settings.

Conclusions. Apoptosis is observed within prostate tissue, but this effect has no clinical significance and cannot lead to prostate shrinkage. In part, this is due to stem cells that are responsible for prostate tissue regeneration and are resistant to apoptosis triggered by α_1 -receptor antagonists.

Key Words: α_1 -receptor antagonists \diamond benign prostate hyperplasia \diamond apoptosis \diamond stem/progenitors cells

INTRODUCTION

α_1 -adrenoreceptor antagonists, such as terazosin and doxazosin are able to induce programmed cell death (apoptosis) within prostate epithelial and mesenchymal cells [1, 2]. In theory, α_1 -adrenoreceptor antagonist treatment with ensuing apoptosis of prostate epithelial and mesenchymal cells should lead to prostate shrinkage. However, clinically, α_1 -adrenoreceptor antagonists treatment does not result in prostate volume reduction. This review is designed to 1) analyze the possible pitfalls related to this discrepancy and 2) to demonstrate how stem cell differentiation could influence in vitro and in vivo results presented in this field.

METHODS

PubMed and DOAJ were searched for papers related to prostate, apoptosis, and stem cells. The following key words were used; prostate, benign prostate hyperplasia, programmed cell death, apoptosis, cell death, α_1 -adrenoreceptor antagonist, α -blockade, prostate epithelium, prostate stroma, stem cells, progenitors, and in vitro models.

Stem cell classification

Stem cells are classified according to their mitotic and differentiating potential. This potential can be described as the possibility to regenerate tissue, or-

gans, or even a whole new organism. These properties can be described as unipotential, multipotential, pluripotential, or totipotential. Totipotential stem cells possess the ability to build a whole new organism. Pluripotential stem cells isolated from an embryo inner cell mass can differentiate into all cells, but cannot form a new organism. Epithelial, endothelial, and mesenchymal stem cells are referred as multipotential. Progenitors or unipotential stem cells can regenerate only one defined cell population. Multipotential and unipotential cells are isolated from tissues of adult organisms, so they are usually called „Adult Stem Cells” (ASC). On the other hand many authors suggested that cells with pluripotential characteristics can be isolated from adults, so this classification will probably be changed in the near future [3, 4].

Stem cells and progenitors regenerate prostate epithelium

Adult stem cells (ASC) are able to self renew and maintain the structural and functional integrity of their original tissue. Transit amplifying cells (TAC) are committed progenitors within ASC and their terminally differentiated daughter cells. ASC and TAC are protected and controlled in their self-renewing capacity and differentiation. ASC and TAC occurrence have been considered in many human tissues including prostate epithelium [5, 6]. The prostatic epithelium is composed of five cell type compartments: stem cells, basal epithelial cells, TAC, neuroendocrine cells, and secretory epithelial cells [7]. Basal cells form a single layer on the basement membrane. The stem cells are localized within the basal layer. Prostate epithelial stem cells provide progenitors that differentiate down either a neuroendocrine or exocrine pathway. The maturation along the exocrine pathway initially involves TAC, which differentiate into intermediate cells. These intermediate cells migrate into the luminal layer where they terminally differentiate into non-proliferative secretory luminal cells [8].

Generally two populations of cells capable of regenerating prostatic ducts can be distinguished. The first population (with considerable huge growth potential) resides in the proximal region of ducts and in the urethra, and the survival of these cells does not require the presence of androgens. The second population (with more limited growth potential) is found in the remaining ductal regions and requires androgens for survival [9]. The prostate epithelial basal cells express high levels of integrin $\alpha 2\beta 1$ and this population can be subdivided into basal stem ($\alpha 2\beta 1(\text{hi})$ CD133+) and TAC ($\alpha 2\beta 1(\text{hi})$ CD133-) [10].

The behavior of CD133+ cells in vitro culture resembled progenitors properties. The viability of these cells after detachment reached 100% in some cases, but the proliferation rate was lower when comparing to CD133(+)/CD133(-) co-cultures. CD133(-) cultures are probably composed of differentiated cells without clonogenic potential. CD133(-) cells had no potential for in vitro proliferation, even in the serum conditioned medium. It can be speculated that CD133(-) cells probably have no ability to regenerate the prostate ducts. These cells were not able to anchor and form monolayer [11]. Some of them can be alive in culture, but the most of them enter an apoptotic pathway. The apoptotic inductions among these cells were probably due to the lack of anchor growth [2, 12].

Receptor status and cell differentiation

Receptor status is supposed to be the most important part of the molecular target in the BPH treatment [13, 14]. It is relevant only with the assumption that prostatic tissue is homogenous. In fact, prostate tissue has two major cell populations: epithelial and mesenchymal. These cells have different origin and function, but interactions between them are well recognized [15, 16]. These interactions are crucial for gland development, tissue hemostasis, and prostate hyperplasia etiology, as well. Moreover, both populations i.e. epithelial and mesenchymal have differentiating cells. The process of differentiation starts from stem cells (or progenitors) to the fully differentiated progenies [6, 9]. The receptor status has to be analyzed in the light of cell origin and its differentiation, as well. This obvious but underestimated issue is often omitted.

How do antagonists of α_1 -receptor induce apoptosis within prostate epithelial cell?

It has been previously reported that doxazosin and terazosin pro-apoptotic activity was independent of its capacity to antagonize α_1 -adrenoreceptors on prostate cells. Many pathways leading to apoptosis within the prostate have been proposed [17–25]. The recent results show that doxazosin triggers apoptosis within benign and malignant prostate cells via an imprecisely defined receptor mechanism related to the tumor necrosis factor receptor family (TNFRs) [24–28]. TNFRs such as CD95 (FAS), TNFR-1, TNFR-2, and CD40 may be responsible for triggering apoptosis [29, 30]. Oligomerized CD95 forms a death-inducing signaling complex. Two signaling pathways (type I and II) have been identified [31, 32]. TNFR-1 and TNFR-2 have significant homology in their extracel-

lular domains; however, their cytoplasmic domains are different. TNFR-1 and TNFR 2 were able to mediate information for cell survival as well as apoptotic signals. CD40 can mediate both proapoptotic and antiapoptotic signals [33, 34, 35]. Trimerization is an active status of TNF family receptors. Trimerization occurs after ligand binding or spontaneously [36, 37]. The counterbalance of TNFRs plays a crucial role in apoptotic response within prostate epithelial cells. Doxazosin increased TNF receptor expression and probably supports the naturally occurring up-regulation of the TNF family of receptors. Doxazosin had an effect on CD40 and CD95 expression on the prostate epithelium [25]. All these findings confirm previous reports that doxazosin triggered apoptosis within the prostate epithelium via the TNF family-related proteins. Initiation of apoptosis was a result of these proteins crosstalk rather than a single receptor-dependent pathway activation. TNF receptor self-assembly process should be recognized as one of the potential mechanisms of triggering apoptosis after doxazosin treatment.

Stem cells can be found within prostate cell lines – implications

Models of primary cell cultures are not popular in investigational medicine. The primary culture implies a culture of cells established immediately after tissue isolation. The goal of the primary culture is their uniqueness, i.e. the patient. Primary cultures offer a unique possibility of performing repeatable tests on the material derived from the patient. It is very difficult to find in laboratory conditions, the model reflecting the process of stem cell or progenitor maturation and differentiation. It is reasonable to extrapolate that primary cultures *in vitro* can be such a simplified model illustrating the dependencies that exist between stem cells and their differentiated progenies [38, 39]. Immortalized or cancer cell lines are often used for *in vitro* studies. The results elaborated on established cell lines are burdened with an error arising from the lack of diversity in terms of cell aging and differentiation. Immortalized and tumor cell lines do not undergo the process of replicational aging, which is equivalent to the aging process characteristic for *vivo* conditions [40, 41]. On the other side primary cultures give the opportunity to study the impact of cell age within growing *in vitro* colonies [7, 42–45]. The morphology of cells in the primary cultures at the time of their establishment tends to reflect on the importance of stem cells and differentiated in the primary cultures originated from normal or cancer cells. In the clusters of cells that give rise to the primary cul-

tures, the progenitor cells are found [46]. They can be combined, e.g. with fragments of basement membrane and contain the other cells forming a niche of normal stem cells [7, 45]. Stem cells give rise to epithelial cell cultures *in vitro*, whereas differentiated cells have inferior properties in this regard. Each digested and prepared for *in vitro* culture tissue must have a certain number of progenitor cells, whose potential determines an appropriate number of divisions. The proliferation of stem cells gives rise to a colony of intensive and long-dividing cells (holoclones). Cells with low ability to proliferate form colonies of paraclones, which probably do not contain stem cells [42, 43, 44].

The proper understanding of *in vitro* models, used for research purposes, should be linked to the heterogeneity of degree of cell differentiation. Under this assumption, when examining the effect of different substances on an established cell line, one can demonstrate on a heterogenous group of cells with varying degrees of differentiation and proliferative potential, different receptor expression, and resistance to drugs [47]. Experiments based on an accepted model of “homogenous” population representing established, immortalized, or cancerous cell lines may lead to false results. *In vitro* experiments on such “homogenous” cell lines inform us only about the overall toxicity of the tested substance or drug. Results obtained from “homogenous” or “primary cell culture–heterogenous” *in vitro* culture models can be different. An example is the influence of doxazosin (an α_1 -receptor antagonist), which induces apoptosis in the epithelial cells and prostate’s stroma *in vitro* [2, 17, 23, 25, 26]. The primary culture of the prostate’s epithelium is composed of stem cells and differentiated cells [7, 11, 45, 48, 49]. High concentrations of doxazosin lead to massive apoptosis of prostate cells when immortalized or cancer cell lines are tested [2, 26, 32]. On the other hand, the same high concentrations of doxazosin trigger apoptosis within only a small amount of prostate epithelial stem cells [50]. The same complex at the same concentration tested on a whole cell population, stem cells, or on differentiated cells can exert different effects [41]. Stem cells and differentiated cells show different sensitivity to different cytotoxic agents, inducing apoptosis. Therefore, contrasting conclusions can be drawn when analyzing different populations such as stem and differentiated cells.

The proper information from *in vitro* cytotoxic tests have been obtained only when primary cultures are analyzed with an emphasis on separate analysis for stem and differentiated cells. Primary cultures showed heterogeneity of cell differentiation. It is very difficult to perform separation of stem and dif-

ferentiated cells within established immortalized or cancer cell lines [51]. Although it is believed that models of heterogeneous primary cultures of normal cells have their counterparts in the tumor cell culture. As a result it can be assumed that in the cancer cell lines, heterogeneity in terms of differentiation is also observed [52–56]. Cancer cultures also have a population of stem cells that are responsible for their growth and other characteristics of a tumor's biological properties [55, 57]. The mechanisms responsible for cell resistance against medicines and other substances vary between stem cells and differentiated cells [6, 58, 59, 60]. The analysis of the results of *in vitro* cytotoxicity tests should be based on separate analysis describing the cytotoxicity for stem cells and separate analysis describing the cytotoxicity for differentiated cells. The model of the heterogeneous cancer cell line is still a simplified model and needs to be developed. This model partially explains discrepancies between the results obtained from *in vitro* experiments and those from clinical practice. With the rapidly developing techniques of cell isolation it is not just a theoretical model, but it can be used in studying the effects of a substance's *in vitro* influence, probably helping to predict the real drug effectiveness [41].

Stem cells are resistant to apoptotic stimuli – Is it the key?

Are stem cells important for the treatment of BPH patients? Normal prostate epithelial stem cells and progenitors were identified and found to have a basal cell phenotype together with the expression of CD133 antigen [56, 61]. Several methods of stem cell isolation were reported [48, 62, 63]. It was proven that progenitor cells were responsible for primary prostate epithelial cultures *in vitro* growth [7, 8, 11, 45]. Is it important for BPH patient treatment to recognize stem cell populations? The stem cell population is very small and located only in the proximal parts of the prostatic ducts. This population has not been regarded as an important part of *in vitro* experimental methodology. However, more recently, it has been recognized that stem cells may be valuable crucial for drug testing experiments. Stem cells are characterized by low sensitivity to action of proapoptotic agents, which is correlated with

high expression of antiapoptotic proteins, high ability to repair damaged DNA, and high expression of ATP-binding cassette drug transporters [50, 58, 59, 60, 64].

It has been demonstrated that α_1 -adrenoreceptor antagonists, such as terazosin and doxazosin induce prostate programmed cell death (apoptosis) without affecting cell proliferation *in vivo* and *in vitro* via α_1 -adrenoreceptor-independent actions [1, 2, 24]. The α_1 -adrenoreceptor antagonist treatment leads to apoptosis of prostate epithelial and mesenchymal cells. However, stem cell compartmentalization may preclude effects on prostate volume reduction. Several studies support the concept that a subpopulation of stem cells resides among basal cells, which is capable of giving rise to other stem cells, basal epithelial, luminal epithelial, and neuroendocrine cells [4, 9, 10, 45, 49, 61, 63, 65, 66]. It has been shown that prostatic epithelial tissue contained a side population constituting 1–1.38% of the epithelial cells and exhibiting low cell cycle activity [4, 45, 48, 62]. It was shown that only a few CD133 positive cells can form a prostatic epithelium in animal and human models [11, 48]. Doxazosin decreases cell number within co-cultures of stem and differentiated prostatic epithelial cells, but stem/progenitor cells are generally not sensitive to doxazosin treatment. There is a suspicion that the differential influence of doxazosin on progenitor and differentiated cells can be responsible for lack of prostate volume decrease after α_1 -antagonist treatment [50].

CONCLUSIONS

1. Prostate epithelial and mesenchymal compartments have stem (progenitors) and differentiating cells.
2. Cell lines used in experimental setting have stem and differentiating cells.
3. α_1 -receptor antagonists, doxazosin and terazosin, induce apoptosis with prostate differentiated epithelial cells.
4. Stem cells/progenitors are resistant to α_1 -receptor antagonists, doxazosin and terazosin.
5. Apoptosis can be evoked within prostate tissue, but this effect has no clinical significance and cannot lead to prostate shrinkage, since stem cells are still able to regenerate prostate tissue.

References

1. Chon JK, Borkowski A, Partial AW, Isaacs JT, Jacobs SC, Kyprianou. α_1 -adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. *J Urol.* 1999; 161: 2002–2008.
2. Walden PD, Globina Y, Nieder A. Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase. *Urol Res.* 2004; 32: 261–265.

3. Ratajczak MZ, Zuba-Surma EK, Machalinski B, Ratajczak J, Kucia M. Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance. *Stem Cell Rev.* 2008; 4: 89–99.
4. Mimeault M, Batra SK. Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. *Stem Cell Rev.* 2008; 4: 27–49.
5. Diaz-Flores L Jr, Madrid JF, Gutierrez R, Varela H, Valladare SF, Alvarez-Argüelles H, Díaz-Flores L. Adult stem and transit-amplifying cell location. *Histol Histopathol.* 2006; 21: 995–1027.
6. Mimeault M, Mehta PP, Hauke R, Batra SK. Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. *Endocr Rev.* 2008; 29: 234–252.
7. Peehl DM. Primary cell cultures as models of prostate cancer development. *Endocrine-Related Cancer.* 2005; 12: 19–47.
8. Uzgaré AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. *J Cell Biochem.* 2004; 91: 196–205.
9. Goto K, Salm SN, Coetzee S, Xiaozhong X, Burger PE, Shapiro E, et al. Proximal prostatic stem cells are programmed to regenerate a proximal–distal ductal axis. *Stem Cells.* 2006; 24: 1859–1868.
10. Heer R, Collins AT, Robson CN, Shenton BK, Leung HY. KGF suppresses alpha2beta1 integrin function and promotes differentiation of the transient amplifying population in human prostatic epithelium. *J Cell Sci.* 2006; 119: 1416–1424.
11. Drewa T, Styczynski J. Progenitor cells are responsible for formation primary epithelial cultures in the prostate epithelial model. *Int Urol Nephrol.* 2007; 39: 851–857.
12. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? *Cancer Res.* 2005; 65: 11230–11235.
13. Soultz N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGF β 1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. *Int J Oncol.* 2006; 29: 305–314.
14. Zhao H, Ramos CF, Brooks JD, Spandidos DA. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. *J Cell Physiol.* 2007; 210: 111–121.
15. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiaozhong X, et al. Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal–epithelial signaling pathways. *PLoS One.* 2010; 5: e13024.
16. Xin L, Ide H, Kim Y, Dubey P, Witte ON. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. *Proc Natl Acad Sci USA.* 2003; 100: 11896–11903.
17. Kyprianou N, Benning CM. Suppression of human prostate cancer cell lines by α -1 adrenoreceptor antagonists doxazosin and terazosin via induction of apoptosis. *Cancer Res.* 2000; 60: 4550–4555.
18. Siddiqui EJ, Shabbir M, Thompson CS, Mumtaz FH, Mikhailidis DP. Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved. *Anticancer Res.* 2005; 25: 4281–4266.
19. Arencibia JM, Del Rio M, Bonnín A, Lopes R, Lemoine NR, López-Barahona M. Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation. *Int J Oncol.* 2005; 27: 1617–1623.
20. Tahmatzopoulos A, Sheng S, Kyprianou N. Maspin sensitizes prostate cancer cells to doxazosin induced apoptosis. *Oncogene.* 2005; 24: 5375–5383.
21. Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. *J Cell Biochem.* 2005; 94: 374–388.
22. Shaw YJ, Yang YT, Garrison JB, Kyprianou N, Chen CS. Pharmacological exploitation of the α 1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. *J Med Chem.* 2004; 47: 4453–4462.
23. Partin JV, Anglin IE, Kyprianou N, Kyprianou N, Chen CS. Quinazoline-based α -1 adrenoreceptor antagonists induce prostate cancer cell apoptosis via TGF- β signaling and I- κ -B α induction. *Br J Cancer.* 2003; 88: 1615–1621.
24. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. *J Urol.* 2003; 169: 1520–1525.
25. Drewa T, Wolski Z, Misterek B, Debski R, Styczynski J. The influence of α 1-antagonist on the expression pattern of TNF receptor family in primary culture of prostate epithelial cells from BPH patients. *Prostate Cancer Prostatic Dis.* 2008; 11: 88–93.
26. Garrison JB, Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. *Cancer Res.* 2006; 66: 464–472.
27. Sasaki Y, Ahmed H, Takeuchi T, Moriyama N, Kawabe K. Immunohistochemical study of Fas, Fas ligand and interleukin-1- β converting enzyme expression in human prostatic cancer. *Br J Urol.* 1998; 81: 852–855.
28. Furuya Y, Fuse H, Masai M. Serum soluble Fas level for detection and staging of prostate cancer. *Anticancer Res.* 2001; 21: 3595–3598.
29. Coffey RN, Watson RW, Fitzpatrick JM. Signaling for the caspases: their role in prostate cell apoptosis. *J Urol.* 2001; 165: 5–14.
30. Frost PJ, Belldegrún A, Bonavida B. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis. *Prostate.* 1999; 41: 20–30.
31. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. *EMBO J.* 1998; 17: 1675–1687.
32. Rokhlin O, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. *Cancer Res.* 1998; 58: 5870–5875.
33. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. *Science.* 1998; 281: 1305–1308.
34. Lens SM, Tesselaar K, den Drijver BR, van Oers MH, van Lier RA. A dual role for both CD40-ligand and TNF- α in controlling human B cell death. *J Immunol.* 1996; 156: 507–514.
35. Screaton G, Xu X-N. T cell life and death signaling via TNF receptor family members. *Curr Opin Immunol.* 2000; 12: 316–322.
36. Tourneur L, Buzyn A, Chiocchia G. FADD adaptor in cancer. *Med Immunol.* 2005; 4: 1.
37. Roesler J, Izquierdo JM, Ryser M, Rosen-Wolf A, Gahr M, Valcarcel J, et al. Haploinsufficiency, rather than the effect of an excessive

- production of soluble CD95 (CD95(D)TM), is the basis for ALPS Ia in a family with duplicated 30 splice site AG in CD95 intron 5 on one allele. *Blood*. 2005; 106: 1652–1659.
38. Peehl DM, Sellers RG. Cultured stromal cells: an in vitro model of prostatic mesenchymal biology. *Prostate*. 2000; 45: 115–123.
39. Wei N, Flaschel E, Friehs K, Nattkemper TW. A machine vision system for automated non-invasive assessment of cell viability via dark field microscopy, wavelet feature selection and classification. *BMC Bioinformatics*. 2008; 9: 449.
40. Zeng X. Human embryonic stem cells: mechanisms to escape replicative senescence? *Stem Cell Rev*. 2007; 3: 270–279.
41. Wesserling M, Drewa T. Will in vitro tests replace animal models in experimental oncology? *J Tissue Sci Eng*. 2011; 2: 102e.
42. Papini S, Cecchetti D, Campani D, Fitzgerald W, Grivel JG, Chen S, et al. Isolation and clonal analysis of human epidermal keratinocyte stem cells in long-term culture. *Stem Cells*. 2003; 21: 481–494.
43. Pellegrini G, Ranno R, Stracuzzi G, Bondanza S, Guerra L, Zambruno G, et al. The control of epidermal stem cells (holoclones) in the treatment of massive full-thickness burns with autologous keratinocytes cultured on fibrin. *Transplantation*. 1999; 68: 868–879.
44. Barrandon Y, Green H. Three clonal types of keratinocyte with different capacities for multiplication. *Proc Natl Acad Sci USA*. 1987; 84: 2302–2306.
45. Miki J, Rhim JS. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. *Prostate Cancer Prostatic Dis*. 2008; 11: 32–39.
46. Chai JK, Sheng ZY, Ma ZF, Yang HM, Liu Q, Liang LM. Growth activity of epidermal cells from different parts of human body. *Chin Med J (Engl)*. 2007; 120: 1444–1447.
47. Drewa T, Czerwinski M, Olkowska J. Stem cells within established cancer cell lines: an impact on in vitro experiments. *Stem Cell Stud*. 2011; doi: 10.4081/scs.2011.e7.
48. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. *J Cell Sci*. 2004; 117: 3539–3545.
49. Planz B, Tabatabaei S, Kirley SD, Aretz HT, Wang QiFa, Lin C-W, et al. Studies on the differentiation pathway and growth characteristics of epithelial culture cells of the human prostate. *Prostate Cancer Prostatic Dis*. 2004; 7: 73–83.
50. Drewa T, Wolski Z, Pokrywka L, Misterek B, Dębski R, Styczyński J. α -blockade is not effective in decreasing tissue bulk in patients suffering from BPH, an in vitro study. *Central Eur J Urol*. 2009; 64: 263–265.
51. Pfeiffer MJ, Schalken JA. Stem cell characteristics in prostate cancer cell lines. *Eur Urol*. 2010; 57: 246–254.
52. Wei C, Guomin W, Yujun L, Ruizhe Q. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? *Cancer Biol Ther*. 2007; 6: 763–768.
53. Yoo MH, Hatfield DL. The cancer stem cell theory: is it correct? *Mol Cells*. 2008; 26: 514–516.
54. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea – a paradigm shift. *Cancer Res*. 2006; 66: 1883–1890.
55. Tirino V, Desiderio, V d'Aquino R, Da Francesco F, Pirozzi G, Galderisi V, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. *PLoS One*. 2008; 3: e3469.
56. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2– cancer cells are similarly tumorigenic. *Cancer Res*. 2005; 65: 6207–6219.
57. Collins AT, Berry PA, Hyde C, Zhou J, Claypool K, Tang DG. Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res*. 2005; 65: 10946–10951.
58. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. *J Clin Pharmacol*. 2005; 45: 872–877.
59. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). *J Cell Sci*. 2000; 113: 2011–2021.
60. Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. *Curr Opin Pharmacol*. 2006; 6: 350–354.
61. Rizzo S, Attard G, Hudson DL. Prostate epithelial stem cells. *Cell Prolif*. 2005; 38: 363–374.
62. Bhatt RI, Brown MD, Hart CA, Gilmore P, Ramani VAC, George NJ, et al. Novel method for the isolation and characterisation of the putative prostatic stem cell. *Cytometry A*. 2003; 54: 89–99.
63. Ravindranath N, Dym M. Isolation of rat ventral prostate basal and luminal epithelial cells by the STAPUT technique. *Prostate*. 1999; 41: 173–180.
64. Drewa T, Styczyński J, Szczepanek J. Is the cancer stem cell population “a player” in multi-drug resistance? *Acta Pol Pharm*. 2008; 65: 493–500.
65. Romanska H, Salagierski M, Bruton R, Abel P, Sosnowski M, Lalani Eln. Doxazosin induces apoptosis in PTEN-positive androgen-independent PC cells via inhibition of Akt activation. *Central Eur J Urol* 2010; 63: 91–97.
66. Bajek A, Pokrywka Ł, Wolski Z, Dębski R, Drewa T. Prostate epithelial stem cells are resistant to apoptosis after α 1-antagonist treatment. The impact for BPH patients. *Central Eur J Urol* 2011; 64: 256–257. ■